Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 A Guide to In Vitro CYP Inhibition Studies | Contract Pharma

What are you searching for?

Sign in
Sponsored Content

A Guide to In Vitro CYP Inhibition Studies

Elements of Study Design and Important Considerations in Data Analysis

Released By BioIVT

The USFDA, along with other regulatory agencies such as the EMA in Europe and PMDA in Japan, recommend evaluating investigational drugs for their potential to be the victim or perpetrator of drug interactions in order to improve the drug’s effectiveness and safety. In a recent presentation, an overview of enzyme inhibition studies is provided along with critical considerations in study design, from determination of supporting data to conclusive interpretation; frequently asked questions; and recommendations for successful regulatory submission. The following article captures the main points of this presentation.

Common Terms When Discussing CYP inhibition

  • Cytochrome P450s (CYPs) are membrane-bound, heme-containing enzymes.
  • The perpetrator, or precipitant, is the drug causing the interaction and an inhibitor of drug metabolizing
  • The victim, or object, is the affected drug and is a substrate of one or more affected enzymes.

Request more information from BioIVT

Request more information from BioIVT

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters